Show simple item record

dc.contributor.authorGallagher, James
dc.contributor.authorByrne, Stephen
dc.contributor.authorWoods, Noel
dc.contributor.authorLynch, Deirdre
dc.contributor.authorMcCarthy, Suzanne
dc.date.accessioned2015-08-17T09:00:21Zen
dc.date.available2015-08-17T09:00:21Zen
dc.date.issued2014-04-17en
dc.identifier.citationBMC Health Services Research. 2014 Apr 17;14(1):177en
dc.identifier.urihttp://dx.doi.org/10.1186/1472-6963-14-177en
dc.identifier.urihttp://hdl.handle.net/10147/567104en
dc.description.abstractAbstract Background Pharmacist interventions are one of the pivotal parts of a clinical pharmacy service within a hospital. This study estimates the cost avoidance generated by pharmacist interventions due to the prevention of adverse drug events (ADE). The types of interventions identified are also analysed. Methods Interventions recorded by a team of hospital pharmacists over a one year time period were included in the study. Interventions were assigned a rating score, determined by the probability that an ADE would have occurred in the absence of an intervention. These scores were then used to calculate cost avoidance. Net cost benefit and cost benefit ratio were the primary outcomes. Categories of interventions were also analysed. Results A total cost avoidance of €708,221 was generated. Input costs were calculated at €81,942. This resulted in a net cost benefit of €626,279 and a cost benefit ratio of 8.64: 1. The most common type of intervention was the identification of medication omissions, followed by dosage adjustments and requests to review therapies. Conclusion This study provides further evidence that pharmacist interventions provide substantial cost avoidance to the healthcare payer. There is a serious issue of patient’s regular medication being omitted on transfer to an inpatient setting in Irish hospitals.
dc.language.isoenen
dc.subjectHEALTH ECONOMICSen
dc.subjectPHARMACYen
dc.subjectHOSPITALSen
dc.titleCost-outcome description of clinical pharmacist interventions in a university teaching hospitalen
dc.language.rfc3066enen
dc.rights.holderGallagher et al.; licensee BioMed Central Ltd.en
dc.date.updated2015-08-14T13:25:48Zen
refterms.dateFOA2018-08-27T03:40:26Z
html.description.abstractAbstract Background Pharmacist interventions are one of the pivotal parts of a clinical pharmacy service within a hospital. This study estimates the cost avoidance generated by pharmacist interventions due to the prevention of adverse drug events (ADE). The types of interventions identified are also analysed. Methods Interventions recorded by a team of hospital pharmacists over a one year time period were included in the study. Interventions were assigned a rating score, determined by the probability that an ADE would have occurred in the absence of an intervention. These scores were then used to calculate cost avoidance. Net cost benefit and cost benefit ratio were the primary outcomes. Categories of interventions were also analysed. Results A total cost avoidance of €708,221 was generated. Input costs were calculated at €81,942. This resulted in a net cost benefit of €626,279 and a cost benefit ratio of 8.64: 1. The most common type of intervention was the identification of medication omissions, followed by dosage adjustments and requests to review therapies. Conclusion This study provides further evidence that pharmacist interventions provide substantial cost avoidance to the healthcare payer. There is a serious issue of patient’s regular medication being omitted on transfer to an inpatient setting in Irish hospitals.


Files in this item

Thumbnail
Name:
12913_2013_Article_3137.pdf
Size:
200.3Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record